Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

Medivation

Status and phase: Completed; Phase 2; Phase 1

Conditions: Huntington's Disease

Treatments: Drug: Dimebon

Study type: Interventional

Funder types: NETWORK; Industry

Identifiers

NCT00387270

DIM03

DIMOND

Details and patient eligibility

About

This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical features of Huntington's disease and a confirmatory family history of HD, or a CAG repeat expansion greater than or equal to 36
• Stage I,II,III HD and a total functional capacity greater than or equal to 5 on the Unified Huntington's Disease Rating Scale

Exclusion criteria

• Clinical evidence of unstable medical illness

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

9 participants in 1 patient group

A

Experimental group

Description:

Dimebon

Treatment:

Drug: Dimebon